Clinical Trial

Tailored Sonidegib Schedule After Complete Response in BCC

Study acronym: SONIBEC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors are administered a tailored schedule of the study drug. The tailored schedule consists of a change in the time of drug assumption. It implements some weeks of assumption and some weeks of suspension of sonidegib rather than a continuous administration.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-03-17; most recent amendment 2026-05-29.
Status change: Recruiting → Active, Not Recruiting 2026-05-29
Trial Details
NCT Number NCT04806646
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Conditions Locally Advanced Basal Cell Carcinoma
Enrollment 21 participants
Start Date 2021-01-12
Primary Completion 2024-12-22 (estimated)
Study Completion 2026-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-01